Table 3.
NOS inhibitors and research conducted on them [134,135,136,137,138,139,140,141,142,143,144,145,146].
| Inhibitor Name | Country/Continent | Application in Clinical Test/Research | References |
|---|---|---|---|
| Tilarginine (L-NMMA) |
North America, Europe | Patients with cardiogenic shock; patients with breast cancer | [134,135,136] |
| N(G)-nitro-L-arginine methyl ester (L-NAME) |
North America, Asia | Patients with cardiogenic shock; patients with septic shock | [137,138] |
| Asymmetric dimethylarginine (ADMA) | Europe | Possible use as a cardiovascular risk factor | [139,140] |
| N(G)-methyl-l-arginine hydrochloride | Europe | Used to restore the balance of vasomotor tone in patients with septic shock | [141,142] |
| 7-nitroindazole (7-NI) | Europe, North America | Anticonvulsive properties in seizure models in rodents | [143,144] |
| Aminoguanidine | Asia | Alleviation of graft-versus-host disease in mice; alleviation of the susceptibility of mice to bacterial infections | [145,146] |